4 results about "Activity daily" patented technology

Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and y-aminobutyric acid (GABA) / glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating an Autism Spectrum Disorder (ASD).

Embodiments of the present application disclose a care list generation method and related device, which are used for efficiently generating a care list. The method comprises: displaying a care list ungenerated state of multiple patients; obtaining unstructured information of a target patient in the multiple patients according to a list generation instruction input by a user for the target patient, wherein the unstructured information comprises target medical order information, target nursing level information, target medical record information, target basic activities of daily living (BADL) assessment information and target risk assessment information; obtaining corresponding target generation information according to the unstructured information, wherein the target generation information comprises multiple groups of target BADL task information groups, multiple groups of target risk task information groups, multiple groups of target medical order task information groups, multiple groups of target operation task information groups and a target patrol task information group, and each task information group comprises a task type, a task name, a task point, a task frequency and a task time; and displaying the care list for the target patient, which comprises the target generation information.

The present disclosure provides a method of treating Dementia with Lewy Bodies (DLB) in a subject, comprising administering to the subject a therapeutically effective amount of a compound of formula Compound I or a pharmaceutically acceptable salt thereof. The method improves cognition, activities of daily living, neuropsychiatric symptoms, and motor symptoms in the subject. The compound may be administered orally for about 6 months or longer, with a total daily dose of about 100 mg to about 300 mg. The method results in improvements in various assessment scales including Montreal Cognitive Assessment Scale (MOCA), Cognitive Drug Research Battery (CDR), Clinician Assessment of Fluctuation (CAF), Alzheimer's Disease Cooperative Study - Activities of Daily Living (ADCS-ADL), Neuropsychiatric Inventory (NPI), and Unified Parkinson's Disease Rating Scale (UPDRS).

Disease modification of specific neurodevelopmental disorders is demonstrated for preschool children through modulation of specific biogenic amine neurotransmitters and γ-aminobutyric acid (GABA) / glutamine. In specific, cumulative reductions in maladaptive behaviors that interfere with activities of daily living for preschool populations are achieved through staged, long term, treatment. Additionally, a prophylaxis for certain neurodegenerative disorders is presented. Provided herein are compositions comprising digestive enzyme preparations and methods of using same for treating neurological disease such as an Autism Spectrum Disorder (ASD).